WO2020145789A1 - 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 - Google Patents
항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 Download PDFInfo
- Publication number
- WO2020145789A1 WO2020145789A1 PCT/KR2020/000611 KR2020000611W WO2020145789A1 WO 2020145789 A1 WO2020145789 A1 WO 2020145789A1 KR 2020000611 W KR2020000611 W KR 2020000611W WO 2020145789 A1 WO2020145789 A1 WO 2020145789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- phosphate
- adalimumab
- histidine
- composition according
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the buffer may further include one or more selected from the group consisting of succinate and acetate.
- composition may have one or more of the following characteristics upon light exposure:
- stable state refers to loss of biological activity and/or loss of structural stability of an antibody (eg, adalimumab) contained in a pharmaceutical composition during a storage period (eg, aggregation, degradation, denaturation (acidic or basic) , Oxidation, etc.) can be understood to mean that 20% or less, 15% or less, 10% or less, or 5% or less, compared to the initial storage.
- adalimumab eg, aggregation, degradation, denaturation (acidic or basic) , Oxidation, etc.
- composition means a preparation that allows the biological activity of the active ingredient to act effectively and does not contain additional ingredients of severe toxicity to the subject to which the composition is administered. .
- the composition may be sterile.
- the antibody may mean an anti-TNF ⁇ antibody, and the anti-TNF ⁇ antibody may mean any antibody that binds TNF ⁇ and regulates its biological activity.
- the anti-TNF ⁇ antibody may be in the form of a full-length antibody or an antibody fragment comprising an antigen-binding site thereof, but is not particularly limited thereto.
- the anti-TNF ⁇ antibody may be a human immunoglobulin G1 (hIgG1) monoclonal antibody, and more specifically, may be adalimumab.
- the buffer may have a pH of about 4.0 to about 8.0, and a pH of about 4.0 to about 7.5, about 4.0 to About 7, about 4.0 to about 6.5, about 4.0 to about 6, about 4.0 to about 5.5, about 4.5 to about 7.5, about 4.5 to about 7, about 4.5 to about 6.5, about 4.5 to about 6, about 4.5 to about 5.5 , About 4.8 to about 7.5, about 4.8 to about 7, about 4.8 to about 6.5, about 4.8 to about 6, about 4.8 to about 5.6, about 5.0 to about 7.5, about 5.0 to about 7, about 5.0 to about 6.5, about 5.0 to about 6, about 5.0 to about 5.5, about 5.2 to about 7.5, about 5.2 to about 7.2, about 5.2 to about 7, about 5.2 to about 6.8, about 5.2 to about 6.6, about 5.2 to about 6.5, about 5.5 to About 7.5, about 5.5 to about 7.2, about 5.5 to about
- a pharmaceutical composition comprising adalimumab, phosphate and histidine, pH 5-7;
- a pharmaceutical composition comprising adalimumab, phosphate, histidine, and mannitol, pH 5-7;
- a pharmaceutical composition comprising adalimumab, phosphate, acetate, histidine, and polysorbate 20, pH 5-7;
- a pharmaceutical composition comprising adalimumab 100 mg/ml, phosphate 2.6 mM, acetate 2.8 mM, and histidine 59 mM, pH 5-7;
- a pharmaceutical composition comprising adalimumab 100 mg/ml, phosphate 2.6 mM, succinate 5 mM, histidine 59 mM, and polysorbate 20 0.08% (w/v), pH 5-7;
- the term'degradate' may mean a low molecular weight product formed by decomposition of an anti-TNF ⁇ antibody protein contained in a pharmaceutical composition provided herein.
- the protein decomposition rate may be expressed as a ratio of decomposition content (%LMW or LMW%) in the composition at any time, and the amount of change in the protein decomposition rate is the content ratio of the decomposition product (small molecule product) in the composition at the start of storage (or storage).
- %LMW or LMW% the amount of change or difference in the ratio of decomposition content (%LMW or LMW%) in the composition after storage (or storage) for a certain period of time
- ⁇ %LMW or ⁇ LMW% [at the start of storage (or storage)]
- the pharmaceutical composition provided herein has an adalimumab aggregation rate of about 15% or less, about 14% or less, and about 13% or less under the light load conditions described in Table 1 of Reference Example 2 below. , About 12% or less, about 11% or less, about 10% or less, about 9% or less, or about 9% or less.
- the device is primarily used for parenteral administration (e.g., subcutaneous, intramuscular, intravenous, intraperitoneal, intrathecal, intraarticular, synovial, and/or intrathecal administration), vials, packs ( pack) in the form of a syringe (e.g., pre-filled syringe; needle size: 20-40G, e.g., 25G, 26G, 27G, 28G, 29G, or 30G), or an anti-TNF ⁇ antibody (e.g., adalimumab)
- a syringe e.g., pre-filled syringe; needle size: 20-40G, e.g., 25G, 26G, 27G, 28G, 29G, or 30G
- an anti-TNF ⁇ antibody e.g., adalimumab
- the unit dosage form may include a syringe ready for injection, including a syringe containing a unit dose (
- Ankylosing spondylitis e.g., Crohn's disease in adults (over 18 years old), Crohn's disease in children (6 to 17 years), etc.
- psoriasis e.g., adults (over 18 years of age)
- children 4 to 17 years old
- psoriatic psoriasis purulent psoriasis
- Hidradenitis Suppurativa ulcerative colitis
- the pharmaceutical composition provided herein may be formulated into a formulation suitable for the route of administration.
- the pharmaceutical composition may be formulated as an injection, an injectable ready-to-use, but is not limited thereto.
- the pharmaceutical composition is formulated such that the total or pharmaceutically effective amount of the anti-TNF ⁇ antibody included, such as adalimumab, is included in one formulation, or two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) may be formulated to be included in divided formulations.
- the formulated composition can be included in unit dosage forms of the devices described above.
- the administration target of the pharmaceutical composition may be selected from mammals including primates (humans, etc.), rodents (mouse, rat, guinea pig, hamster, rabbit, etc.), cats, dogs, pigs, cows, horses, and the like.
- 1B is a graph showing %Monomer (Monomer weight %) of a protein in a formulation under thermal harsh conditions (storing for 4 weeks at 40°C) according to buffer type and histidine inclusion/concentration of the antibody formulation according to an embodiment.
- Figure 2a is a graph showing the %HMW of the protein in the formulation under freeze-melt conditions according to the buffer type and histidine inclusion/concentration of the antibody formulation according to an embodiment.
- Figure 5a is a graph showing the %HMW of the protein in the formulation under thermal harsh conditions (storage at 40°C for 4 weeks) according to the polyol type of the antibody formulation according to an embodiment.
- Figure 5c is a graph showing the %LMW of the protein in the formulation under thermal harsh conditions (storage at 40°C for 4 weeks) according to the polyol type of the antibody formulation according to an embodiment.
- SE-HPLC Size exclusion-High Performance Liquid Chromatography analysis was performed according to the manufacturer's manual using Waters' HPLC system. It is divided into 3 peaks according to retention time (molecular weight of protein), and these 3 peaks are HMW peak (protein aggregation), monomer peak, and LMW peak (protein) in order of short retention time (large protein molecular weight). Decomposition).
Abstract
Description
Claims (41)
- 아달리무맙 40mg/ml 내지 200mg/ml,포스페이트를 포함하는 완충제 및히스티딘을 포함하고,pH 5 내지 7이며,시트레이트, 또는 이의 약학적으로 허용 가능한 염, 또는 이들 모두를 포함하지 않고,포스페이트, 숙시네이트, 및 아세테이트의 약학적으로 허용 가능한 염을 제외한 염은 포함하지 않는, 약학적 조성물.
- 제1항에 있어서,상기 조성물은 히스티딘을 제외한 아미노산을 포함하지 않는 것인, 약학적 조성물.
- 제1항 또는 제2항에 있어서,상기 조성물은 EDTA (Ethylenediaminetetraacetic acid)를 포함하지 않는 것인, 약학적 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 포스페이트, 숙시네이트, 및 아세테이트의 약학적으로 허용 가능한 염을 제외한 염은 염화나트륨, 황산나트륨, 및 염화칼륨으로 이루어진 군에서 선택된 하나 이상인, 약학적 조성물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 완충제는 숙시네이트 및 아세테이트로 이루어진 군에서 선택된 하나 이상을 추가로 포함하는 것인, 약학적 조성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 완충제 농도는 0.5mM 내지 50mM인, 약학적 조성물.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 완충제는(1) 1.7mM 내지 10mM 포스페이트 또는 이의 약학적으로 허용가능한 염, 또는,(2) (i) 1.7mM 내지 10mM 포스페이트 또는 이의 약학적으로 허용가능한 염, 및 (ii) 4.1mM 내지 12mM 숙시네이트, 1.7mM 내지 10mM 아세테이트, 또는 이들의 약학적으로 허용가능한 염 중에서 선택된 1종 이상을 포함하는 것인, 약학적 조성물.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 상기 히스티딘의 농도는 40mM 내지 80mM인, 약학적 조성물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 폴리올을 추가로 포함하는, 약학 조성물.
- 제9항에 있어서, 상기 폴리올은 만니톨, 소르비톨, 수크로오스, 트레할로오스, 말토오스, 락토오스, 자일리톨, 아라비톨, 메글루민, 에리트리톨, 락티톨, 말티톨, 및 이노시톨로 이루어진 군에서 선택된 1종 이상을 포함하는 것인, 약학적 조성물.
- 제9항 또는 제10항에 있어서, 상기 폴리올의 농도는 2 내지 10 %(w/v)인, 약학적 조성물.
- 제9항 내지 제11항 중 어느 한 항 있어서, 상기 폴리올은 만니톨인 것인, 약학적 조성물.
- 제12항 있어서, 상기 만니톨의 농도는 2 내지 5 %(w/v)인, 약학적 조성물.
- 제1항 내지 제13항 중 어느 한 항에 있어서, 계면활성제를 추가로 포함하는, 약학적 조성물.
- 제14항에 있어서, 상기 계면활성제는 폴리소르베이트 20, 폴리소르베이트 80, 또는 이들의 조합을 포함하는 것인, 약학적 조성물.
- 제15항에 있어서, 상기 계면활성제는 폴리소르베이트 20인, 약학적 조성물.
- 제16항에 있어서, 상기 폴리소르베이트 20의 농도는 0.01 내지 0.9 %(w/v)인, 약학적 조성물.
- 제1항 내지 제17항 중 어느 한 항에 있어서, 상기 아달리무맙의 농도는 40mg/ml 내지 100mg/ml인, 약학적 조성물.
- 아달리무맙 40mg/ml 내지 200mg/ml,포스페이트를 포함하는 완충제 및히스티딘을 포함하고,pH 5 내지 7이며,시트레이트, 또는 이의 약학적으로 허용 가능한 염, 또는 이들 모두를 포함하지 않고,포스페이트, 숙시네이트, 및 아세테이트의 약학적으로 허용 가능한 염을 제외한 염은 포함하지 않으며,광 노출 조건에서 상기 아달리무맙의 응집율이 약 15% 이하인 약학적 조성 물
- 제19항에 있어서, 광 노출 조건에서 상기 아달리무맙 중의 메티오닌 잔기의 산화율(%Met256/light-exposured) 변화량(Δ%Met256)이 68% 이하인, 약학적 조성물.
- 제19항 또는 제20항에 있어서,상기 조성물은 히스티딘을 제외한 아미노산을 포함하지 않는 것인, 약학적 조성물.
- 제19항 내지 제21항 중 어느 한 항에 있어서,상기 조성물은 EDTA (Ethylenediaminetetraacetic acid)를 포함하지 않는 것인, 약학적 조성물.
- 제19항 내지 제22항 중 어느 한 항에 있어서, 상기 포스페이트, 숙시네이트, 및 아세테이트의 약학적으로 허용 가능한 염을 제외한 염은 염화나트륨, 황산나트륨, 및 염화칼륨으로 이루어진 군에서 선택된 하나 이상인, 약학적 조성물.
- 제19항 내지 제23항 중 어느 한 항에 있어서, 상기 완충제는 숙시네이트 및 아세테이트로 이루어진 군에서 선택된 하나 이상을 추가로 포함하는 것인, 약학적 조성물.
- 제19항 내지 제24항 중 어느 한 항에 있어서, 상기 완충제 농도는 0.5mM 내지 50mM인, 약학적 조성물.
- 제19항 내지 제25항 중 어느 한 항에 있어서, 상기 완충제는(1) 1.7mM 내지 10mM 포스페이트 또는 이의 약학적으로 허용가능한 염, 또는,(2) (i) 1.7mM 내지 10mM 포스페이트 또는 이의 약학적으로 허용가능한 염, 및 (ii) 4.1mM 내지 12mM 숙시네이트, 1.7mM 내지 10mM 아세테이트, 또는 이들의 약학적으로 허용가능한 염 중에서 선택된 1종 이상을 포함하는 것인, 약학적 조성물.
- 제19항 내지 제26항 중 어느 한 항에 있어서, 상기 히스티딘의 농도는 40mM 내지 80mM인, 약학적 조성물.
- 제19항 내지 제27항 중 어느 한 항에 있어서, 폴리올을 추가로 포함하는, 약학 조성물.
- 제28항에 있어서, 상기 폴리올은 만니톨, 소르비톨, 수크로오스, 트레할로오스, 말토오스, 락토오스, 자일리톨, 아라비톨, 메글루민, 에리트리톨, 락티톨, 말티톨, 및 이노시톨로 이루어진 군에서 선택된 1종 이상을 포함하는 것인, 약학적 조성물.
- 제28항 또는 제29항에 있어서, 상기 폴리올의 농도는 2 내지 10 %(w/v)인, 약학적 조성물.
- 제28항 내지 제30항 중 어느 한 항 있어서, 상기 폴리올은 만니톨인, 약학적 조성물.
- 제31항 있어서, 상기 만니톨의 농도는 2 내지 5 %(w/v)인, 약학적 조성물.
- 제19항 내지 제32항 중 어느 한 항에 있어서, 계면활성제를 추가로 포함하는, 약학적 조성물.
- 제33항에 있어서, 상기 계면활성제는 폴리소르베이트 20, 폴리소르베이트 80, 또는 이들의 조합을 포함하는 것인, 약학적 조성물.
- 제33항에 있어서, 상기 계면활성제는 폴리소르베이트 20인 것인, 약학적 조성물.
- 제35항에 있어서, 상기 폴리소르베이트 20의 농도는 0.01 내지 0.9 %(w/v)인, 약학적 조성물.
- 제19항 내지 제36항 중 어느 한 항에 있어서, 상기 아달리무맙의 농도는 50mg/ml 내지 100mg/ml인, 약학적 조성물.
- 제1항 내지 제37항 중 어느 한 항의 약학적 조성물을 포함하는 디바이스.
- 제38항에 있어서, 상기 약학적 조성물의 정맥 투여 또는 피하 투여를 위한 것인, 디바이스.
- 제38항 또는 제39항에 있어서, 상기 약학적 조성물을 시린지(syringe), 프리필드시린지(pre-filled syringe), 오토인젝터, 보틀, 바이알, 및 튜브로 이루어진 군에서 선택된 용기에 포함하는, 디바이스.
- 제1항 내지 제37항 중 어느 한 항의 약학적 조성물을 상기 항체의 투여를 필요로 하는 환자에게 투여하는 단계를 포함하는, 상기 환자의 치료방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020207124A AU2020207124A1 (en) | 2019-01-11 | 2020-01-13 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
EP20738071.8A EP3909607A4 (en) | 2019-01-11 | 2020-01-13 | PHARMACEUTICAL COMPOSITION WITH ANTIBODIES, DEVICE CONTAINING THIS AND USE THEREOF |
US17/421,770 US20220081478A1 (en) | 2019-01-11 | 2020-01-13 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
CA3125927A CA3125927A1 (en) | 2019-01-11 | 2020-01-13 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
KR1020217021834A KR20210102954A (ko) | 2019-01-11 | 2020-01-13 | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 |
BR112021013497-2A BR112021013497A2 (pt) | 2019-01-11 | 2020-01-13 | Composição farmacêutica compreendendo anticorpo, dispositivo compreendendo o mesmo e uso do mesmo |
IL284587A IL284587A (en) | 2019-01-11 | 2021-07-04 | A pharmaceutical compound containing an antibody, a device containing it, and its use |
US17/380,483 US20210347878A1 (en) | 2019-01-11 | 2021-07-20 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
US17/380,445 US20210347877A1 (en) | 2019-01-11 | 2021-07-20 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962791541P | 2019-01-11 | 2019-01-11 | |
US62/791,541 | 2019-01-11 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/421,770 A-371-Of-International US20220081478A1 (en) | 2019-01-11 | 2020-01-13 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
US17/380,483 Continuation US20210347878A1 (en) | 2019-01-11 | 2021-07-20 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
US17/380,445 Continuation US20210347877A1 (en) | 2019-01-11 | 2021-07-20 | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020145789A1 true WO2020145789A1 (ko) | 2020-07-16 |
Family
ID=71520291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/000611 WO2020145789A1 (ko) | 2019-01-11 | 2020-01-13 | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20220081478A1 (ko) |
EP (1) | EP3909607A4 (ko) |
KR (1) | KR20210102954A (ko) |
AU (1) | AU2020207124A1 (ko) |
BR (1) | BR112021013497A2 (ko) |
CA (1) | CA3125927A1 (ko) |
IL (1) | IL284587A (ko) |
TW (1) | TW202042840A (ko) |
WO (1) | WO2020145789A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022348349A1 (en) * | 2021-09-16 | 2024-05-02 | Aprogen Inc. | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140186361A1 (en) * | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
EP2946765A1 (en) * | 2014-05-23 | 2015-11-25 | Ares Trading S.A. | Liquid pharmaceutical composition |
US20170189527A1 (en) * | 2014-05-23 | 2017-07-06 | Ares Trading Sa | Liquid pharmaceutical composition |
WO2017136433A1 (en) * | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
US20170252437A1 (en) * | 2014-10-28 | 2017-09-07 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018150258A (ja) * | 2017-03-10 | 2018-09-27 | Meiji Seikaファルマ株式会社 | 水性製剤、注射器入り水性製剤及びキット製剤 |
-
2020
- 2020-01-13 WO PCT/KR2020/000611 patent/WO2020145789A1/ko unknown
- 2020-01-13 TW TW109101115A patent/TW202042840A/zh unknown
- 2020-01-13 KR KR1020217021834A patent/KR20210102954A/ko not_active Application Discontinuation
- 2020-01-13 AU AU2020207124A patent/AU2020207124A1/en active Pending
- 2020-01-13 EP EP20738071.8A patent/EP3909607A4/en active Pending
- 2020-01-13 US US17/421,770 patent/US20220081478A1/en active Pending
- 2020-01-13 BR BR112021013497-2A patent/BR112021013497A2/pt unknown
- 2020-01-13 CA CA3125927A patent/CA3125927A1/en active Pending
-
2021
- 2021-07-04 IL IL284587A patent/IL284587A/en unknown
- 2021-07-20 US US17/380,483 patent/US20210347878A1/en active Pending
- 2021-07-20 US US17/380,445 patent/US20210347877A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140186361A1 (en) * | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
EP2946765A1 (en) * | 2014-05-23 | 2015-11-25 | Ares Trading S.A. | Liquid pharmaceutical composition |
US20170189527A1 (en) * | 2014-05-23 | 2017-07-06 | Ares Trading Sa | Liquid pharmaceutical composition |
US20170252437A1 (en) * | 2014-10-28 | 2017-09-07 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
WO2017136433A1 (en) * | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
Non-Patent Citations (2)
Title |
---|
CAS , no. 331731 -18-1 |
See also references of EP3909607A4 |
Also Published As
Publication number | Publication date |
---|---|
BR112021013497A2 (pt) | 2021-09-14 |
TW202042840A (zh) | 2020-12-01 |
IL284587A (en) | 2021-08-31 |
EP3909607A4 (en) | 2022-10-26 |
US20220081478A1 (en) | 2022-03-17 |
CA3125927A1 (en) | 2020-07-16 |
AU2020207124A1 (en) | 2021-07-29 |
KR20210102954A (ko) | 2021-08-20 |
EP3909607A1 (en) | 2021-11-17 |
US20210347877A1 (en) | 2021-11-11 |
US20210347878A1 (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014017845A2 (en) | A liquid formulation of long acting insulinotropic peptide conjugate | |
WO2015080513A1 (en) | A liquid formulation of a fusion protein comprising tnfr and fc region | |
WO2014017847A1 (en) | A liquid formulation of long-acting insulin conjugate | |
WO2014017849A1 (en) | A liquid formulation of long-acting insulin and insulinotropic peptide | |
WO2011090306A2 (en) | Liquid formulations for long-acting erythropoietin conjugate | |
WO2017078385A1 (en) | Formulation of modified interleukin-7 fusion protein | |
WO2018131893A1 (ko) | 안정한 액체 제제 | |
WO2012057525A2 (en) | Liquid formulations of long acting interferon alpha conjugate | |
WO2011090305A2 (en) | Liquid formulations for long-acting g-csf conjugate | |
WO2014084508A1 (ko) | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 | |
WO2020145789A1 (ko) | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 | |
WO2021182874A1 (ko) | 안정성이 증진된 액상 약제학적 조성물 | |
WO2018169348A1 (ko) | 항-tnf 알파 항체의 액상 제제 | |
WO2021010621A1 (ko) | 자가면역질환 및 염증성질환 펩타이드 치료제 | |
WO2013147559A1 (en) | A liquid formulation of highly concentrated long-acting human growth hormone conjugate | |
WO2022005113A1 (ko) | 항-FcRn 항체에 대한 제형 | |
WO2017116191A2 (ko) | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 | |
WO2022045857A2 (ko) | 안정한 약제학적 제제 | |
WO2021096278A1 (ko) | 항체 의약품용 액상 조성물 | |
WO2020101452A1 (ko) | 단백질을 포함하는 안정한 액상 조성물 | |
WO2018080196A2 (ko) | 안정한 약제학적 제제 | |
WO2018066891A2 (ko) | 인터페론 베타 변이체의 안정화 제제 | |
WO2021230460A1 (ko) | Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도 | |
WO2021149945A1 (ko) | Pd-l1 단백질이 포함된 융합 단백질 및 이의 용도 | |
WO2023204554A1 (ko) | 오크렐리주맙을 포함하는 약학적 조성물과 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20738071 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3125927 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20217021834 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021013497 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020207124 Country of ref document: AU Date of ref document: 20200113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021013497 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210708 |
|
ENP | Entry into the national phase |
Ref document number: 2020738071 Country of ref document: EP Effective date: 20210811 |